Study title: A PHASE IV - PHARMACOVIGILANCE STUDY OF KEPPRA(R) GREECE - S.K.A.T.E. : SAFETY OF KEPPRA(R) AS ADJUNCTIVE THERAPY IN EPILEPSY.
| Type of medicine: Centrally authorised medicines | |||||
| Therapeutic area: Nervous System Diseases | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: levetiracetam | |||||
| ATC code: N03AX14 | |||||
| Document link: N01035 - Levetiracetam - RRCE05J1501.pdf | |||||
| Document date: 2011-11-28 | |||||
| Study number: RRCE05J1501 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |